The therapeutic efficacy of 5-ALA based photodynamic therapy and chemotherapy combination in triple negative breast cancer cells
Künye
Erk, B., Kamanli, A. F., & Guney Eskiler, G. (2024). The therapeutic efficacy of 5-ALA based photodynamic therapy and chemotherapy combination in triple negative breast cancer cells. Lasers in Medical Science, 39(1). https://doi.org/10.1007/s10103-024-04141-9 Özet
Triple negative breast cancer (TNBC) is one of the subtypes of breast cancer characterized by a heterogeneous and aggressive nature. Photodynamic therapy (PDT) has drawn signifcant attention in cancer treatment. However, solubility of photosensitizer, penetration problems into a target tissue and insufcient oxygen concentration limit the efectiveness of PDT.
To overcome these limitations and to reduce the side efects of chemotherapy, combination treatment modalities play an
essential role in cancer treatment. In this study, we aimed to investigate the combination efcacy of cisplatin-based chemotherapy and 5-Aminolevulinic acid (5-ALA)/PDT in TNBC cells and healthy breast cells in vitro. To determine the efect of
the combination efects of cisplatin and 5-ALA/PDT on TNBC cells, two treatment protocols (simultaneous and sequential
combination therapy) were evaluated compared with cisplatin and 5-ALA/PDT monotherapy and WST-1, Annexin V assay,
acridine orange (AO) and mitochondrial staining were performed. Our fndings showed that MDA-MB-231 TNBC cell
viability was signifcantly decreased following simultaneous combination treatment compared to cisplatin and 5-ALA/PDT
monotherapy. Additionally, simultaneous combination treatment was more efective than sequential combination treatment.
The simultaneous combination treatment of 2.5 µM cisplatin and 5-ALA/PDT at 6 J/cm2
and 9 J/cm2
induced 46.78% and
53.6% total apoptotic death, respectively in TNBC cells compared with monotherapies (cisplatin (37.88%) and 5-ALA/PDT
(6 J/cm2
: 31.48% and 9 J/cm2
: 37.78%). Additionally, cisplatin and 5-ALA/PDT combination treatment resulted in nuclear
fragmentation and mitochondrial damage due to apoptosis. Our results suggest that cisplatin and 5-ALA/PDT simultaneous
combination therapy could be a promising new alternative strategy for treating TNBC. However, further studies are required
to assess the underlying molecular mechanisms of cisplatin and 5-ALA/PDT combination treatment at the molecular level.